President-elect Donald Trump and his incoming administration are unlikely to attempt a wholesale restructuring of U.S.

Maze Therapeutics has completed a Series D financing round, raising $115m to propel the development of its lead candidates, MZE829 and MZE782.

By Gnaneshwar Rajan and Maggie Fick (Reuters) -U.S.-based vaccine maker Novavax said on Wednesday it will sell its ...

In older patients discharged after hospitalization for heart failure, many spend the majority of the first year alive and at home.

Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...

Navitas Semiconductor is losing money according to Jim Cramer. LandBridge Company is a winner, while Regeneron is facing ...

Comparison measures of lung function and improved categorization of cardiovascular disease (CVD) risk were among the key ...

The Chinese government's policies promoting opening up and innovation, as well as the excellent business environment it fosters for foreign enterprises, have injected strong confidence into Sanofi's ...

Novavax sells manufacturing facility to Novo Nordisk for $200M, enabling Novavax to advance growth strategy and drive value ...

COVID-19 vaccine maker Novavax said on Wednesday it will sell its manufacturing facility in Czech Republic to Wegovy-maker ...

French pharma giant Sanofi will invest some 1 billion euros ($1.05 billion) to establish a new insulin production base in ...

Enveda’s pipeline is led by ENV-294, a first-in-class, oral small molecule being developed to treat atopic dermatitis and other inflammatory conditions by combining the advantages of blockbuster drugs ...